Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T03:09:43.414Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological treatment of violence in schizophrenia

Published online by Cambridge University Press:  25 July 2019

Martin T. Strassnig ,
Vanessa Nascimento ,
Elizabeth Deckler  and
Philip D. Harvey Open the ORCID record for Philip D. Harvey [Opens in a new window]
Martin T. Strassnig
Affiliation:
Department of Psychiatry, University of Miami, Miami, FL, USA
Vanessa Nascimento
Affiliation:
University of Miami, Miller School of Medicine, Miami, FL, USA
Elizabeth Deckler
Affiliation:
University of Miami, Miller School of Medicine, Miami, FL, USA
Philip D. Harvey*
Affiliation:
Department of Psychiatry, University of Miami, Miami, FL, USA Bruce W. Carter VA Medical Center, Miami, FL, USA.
*
* Address correspondence to: Philip D. Harvey, Department of Psychiatry, University of Miami, Miami, FL33136, USA. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Chronic aggression and violence in schizophrenia are rare, but receive disproportionate negative media coverage. This contributes to the stigma of mental illness and reduces accessibility to mental health services. Substance Use Disorders (SUD), antisocial behavior, non-adherence and recidivism are known risk factors for violence. Treatment with antipsychotic medication can reduce violence. Aside from clozapine, long-acting injectable antipsychotics (LAI) appear to be superior to oral antipsychotics for preventing violence, addressing adherence and recidivism. LAI also facilitate the implementation of functional skills training. For the high-risk recidivist target population with schizophrenia, better life skills have the potential to also reduce the risk for contact with the legal system, including an improved ability to live independently in supported environments and interact appropriately with others. High-risk patients who are resistant to treatment with other antipsychotics should receive treatment with clozapine due to its direct positive effects on impulsive violence, along with a reduction in comorbid risk factors such as SUDs.

Keywords

Clozapineviolenceaggressive behaviorlong-acting injectable antipsychoticrelapserecidivisminstitutionalization
Type
Review
Information
CNS Spectrums , Volume 25 , Issue 2 , April 2020 , pp. 207 - 215
Copyright
© Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES:

Citrome, L, Volavka, J. The psychopharmacology of violence: making sensible decisions. CNS Spectr. 2014; 19(5): 411–418.CrossRefGoogle ScholarPubMed
Meyer, JM, Cummings, MA, Proctor, G, et al. Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am. 2016; 39(4): 541–556.10.1016/j.psc.2016.07.012CrossRefGoogle ScholarPubMed
Fazel, S, Gulati, G, Linsell, L, et al. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med. 2009; 6(8): e1000120.10.1371/journal.pmed.1000120CrossRefGoogle ScholarPubMed
Witt, K, van Dorn, R, Fazel, S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One. 2013; 8(2): e55942.10.1371/journal.pone.0055942CrossRefGoogle ScholarPubMed
Sariaslan, A, Lichtenstein, P, Larsson, H, et al. Triggers for violent criminality in patients with psychotic disorders. JAMA Psychiatry. 2016; 73(8): 796–803.CrossRefGoogle ScholarPubMed
Torrey, EF. Stigma and violence: isn’t it time to connect the dots? Schizophr Bull. 2011; 37(5): 892–896.CrossRefGoogle ScholarPubMed
Bhavsar, V, Bhugra, D. Violence towards people with mental illness: assessment, risk factors, and management. Psychiatry Clin Neurosci. 2018; 72(11): 811–820.CrossRefGoogle ScholarPubMed
Walsh, E, Buchanan, A, Fahy, T. Violence and schizophrenia: examining the evidence. Br J Psychiatry. 2002; 180: 490–495.CrossRefGoogle ScholarPubMed
Nolan, KA, Volavka, J, Czobor, P, et al. Aggression and psychopathology in treatment-resistant in patients with schizophrenia and schizoaffective disorder. J Psychiatr Res. 2005; 39(1): 109–115.10.1016/j.jpsychires.2004.04.010CrossRefGoogle ScholarPubMed
Quanbeck, CD, McDermott, BE, Lam, J, et al. Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv. 2007; 58(4): 521–528.10.1176/ps.2007.58.4.521CrossRefGoogle ScholarPubMed
Sirotich, F. The criminal justice outcomes of jail diversion programs for persons with mental illness: a review of the evidence. J Am Acad Psychiatry Law 2009; 37(4): 461–472.Google Scholar
Volavka, J, Van Dorn, RA, Citrome, L, et al. Hostility in schizophrenia: an integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. Eur Psychiatry. 2016; 31: 13–19.CrossRefGoogle ScholarPubMed
Morrissette, DA, Stahl, SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014; 19: 439–448.10.1017/S1092852914000388CrossRefGoogle ScholarPubMed
Patchan, K, Vyas, G, Hackman, AL, et al. Clozapine in reducing aggression and violence in forensic populations. Psychiatr Q. 2018; 89(1): 157–168.10.1007/s11126-017-9521-zCrossRefGoogle ScholarPubMed
Ratey, JJ, Leveroni, C, Kilmer, D, et al. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry. 1993; 54(6): 219–223.Google ScholarPubMed
Rabinowitz, J, Avnon, M, Rosenberg, V. Effect of clozapine on physical and verbal aggression. Schizophr Res. 1996; 22(3): 249–255.10.1016/S0920-9964(96)00051-5CrossRefGoogle ScholarPubMed
Chiles, JA, Davidson, P, McBride, D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Community Psychiatry. 1994; 45(3): 269–271.Google ScholarPubMed
Sinyor, M, Remington, G. Is psychiatry ignoring suicide? The case for clozapine. J Clin Psychopharmacol. 2012; 32(3): 307–308.10.1097/JCP.0b013e31825501fbCrossRefGoogle ScholarPubMed
Brunette, MF, Drake, RE, Xie, H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006; 32(4): 637–643.CrossRefGoogle ScholarPubMed
Misawa, F, Kishimoto, T, Hagi, K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016; 176(2–3): 220–220.10.1016/j.schres.2016.07.018CrossRefGoogle ScholarPubMed
Khan, AY, Salaria, S, Ovais, M, et al. Depot antipsychotics: where do we stand? Ann Clin Psychiatry. 2016; 28(4): 289–298.Google ScholarPubMed
Arango, C, Bombin, I, Gonzalez-Salvador, T, et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry. 2006; 21(1): 34–40.CrossRefGoogle ScholarPubMed
Correll, CU, Citrome, L, Haddad, PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016; 77(Suppl.3): 1–24.CrossRefGoogle ScholarPubMed
Rezansoff, SN, Moniruzzaman, A, Fazel, S, et al. Adherence to antipsychotic medication and criminal recidivism in a Canadian provincial offender population. Schizophr Bull. 2017; 43(5): 1002–1010.CrossRefGoogle Scholar
Lynn Starr, H, Bermak, J, Mao, L, et al. Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: an exploratory analysis of the PRIDE study. Schizophr Res. 2018; 194: 39–46.CrossRefGoogle Scholar
Iozzino, L, Ferrari, C, Large, M, et al. Prevalence and risk factors of violence by psychiatric acute inpatients: a systematic review and meta-analysis. PLoS One. 2015; 10(6): e0128536.CrossRefGoogle ScholarPubMed
Trudeau, KJ, Burtner, J, Villapiano, AJ, et al. Burden of schizophrenia or psychosis-related symptoms in adults undergoing substance abuse evaluation. J Nerv Ment Dis. 2018; 206(7): 528–536.10.1097/NMD.0000000000000835CrossRefGoogle ScholarPubMed
Alphs, L, Benson, C, Cheshire-Kinney, K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015; 76(5): 554–561.CrossRefGoogle ScholarPubMed
Strassnig, M, Bowie, C, Pinkham, AE, et al. Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia? J Psychiatr Res. 2018; 104: 124–129.CrossRefGoogle Scholar
Fu, DJ, Turkoz, I, Walling, D, et al. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the personal and social performance scale compared with placebo in subjects with schizoaffective disorder. Schizophr Res. 2018; 192: 185–193.CrossRefGoogle ScholarPubMed
Montemagni, C, Frieri, T, Rocca, P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 2016; 12: 917–929.Google ScholarPubMed
Sajatovic, M, Ramirez, LF, Fuentes-Casiano, E, et al. A 6-month prospective trial of a personalized behavioral intervention + long-acting injectable antipsychotic in individuals with schizophrenia at risk of treatment nonadherence and homelessness. J Clin Psychopharmacol. 2017; 37(6): 702–707.10.1097/JCP.0000000000000778CrossRefGoogle ScholarPubMed
Medrano, S, Abdel-Baki, A, Stip, E, et al. Three-year naturalistic study on early use of long-acting injectable antipsychotics in first episode psychosis. Psychopharmacol Bull. 2018; 48(4): 25–61.Google Scholar
Krakowski, MI, Czobor, P. Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. Schizophr Bull. 2014; 40(4): 886–894.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006; 63(6): 622-629.10.1001/archpsyc.63.6.622CrossRefGoogle ScholarPubMed
Krakowski, M, Czobor, P, Citrome, L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Rese. 2009; 110(1–3): 95–102.CrossRefGoogle ScholarPubMed
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001; 52(11): 1510–1514.10.1176/appi.ps.52.11.1510CrossRefGoogle ScholarPubMed
Swanson, JW, Swartz, MS, Van Dorn, RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008; 193(1): 37–43.CrossRefGoogle ScholarPubMed
Hodgins, S, Riaz, M. Violence and phases of illness: differential risk and predictors. Eur Psychiatry. 2011; 26(8): 518–524.CrossRefGoogle ScholarPubMed
Swanson, JW, Swartz, MS, Elbogen, EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004; 30(1): 3–20.10.1093/oxfordjournals.schbul.a007065CrossRefGoogle ScholarPubMed
Chengappa, KN, Vasile, J, Levine, J, et al. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res. 2002; 53(1–2): 1–6.10.1016/S0920-9964(00)00175-4CrossRefGoogle Scholar
Fond, G, Boyer, L, Boucekine, M, et al. Illness and drug modifiable factors associated with violent behavior in homeless people with severe mental illness: results from the French Housing First (FHF) program. Prog Neuro-Psychopharmacol & Biol Psychiatry. 2019; 90: 92–96.10.1016/j.pnpbp.2018.11.006CrossRefGoogle ScholarPubMed
Kranzler, H, Roofeh, D,Gerbino-Rosen, G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2005; 44(1): 55–63.10.1097/01.chi.0000145371.23122.5aCrossRefGoogle ScholarPubMed
Chalasani, L, Kant, R, Chengappa, KN. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Can J Psychiatr. 2001; 46(10): 965–968.10.1177/070674370104601010CrossRefGoogle ScholarPubMed
Cohen, SA, Underwood, MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatr. 1994; 55(10): 440–444.Google Scholar
Hotham, JE, Simpson, PJ, Brooman-White, RS, et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violenttreatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectr. 2014; 19(5): 403–410.CrossRefGoogle Scholar
Ifteni, P, Szalontay, AS, Teodorescu, A. Reducing restraint with clozapine in involuntarily admitted patients with schizophrenia. Am J Ther. 2017; 24(22): 222–226.CrossRefGoogle ScholarPubMed
Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J ClinPsychiatry. 1999; 60: 43–46.Google ScholarPubMed
Balbuena, L, Mela, M, Wong, S, et al. Does clozapine promote employability and reduce offending among mentally disordered offenders? Can J Psychiatry. 2010; 55(1): 50–56.CrossRefGoogle ScholarPubMed
Kraus, JE, Sheitman, BB. Clozapine reduces violent behavior in heterogeneous diagnostic groups. J Neuropsychiatr Clin Neurosci. 2005; 17(1): 36–44.CrossRefGoogle ScholarPubMed
Kelly, DL, Conley, RR, Feldman, S, et al. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q. 2006; 77(1): 81–95.CrossRefGoogle ScholarPubMed
Kisely, SR, Campbell, LA. Compulsory community and involuntary outpatient treatment for people with severe mental disorders. Schizophr Bull. 2015; 41(3): 542–543.CrossRefGoogle ScholarPubMed
Swartz, MS, Bhattacharya, S, Robertson, AG, et al. Involuntary outpatient commitment and the elusive pursuit of violence prevention. Can J Psychiatr. 2017; 62(2): 102–108.10.1177/0706743716675857CrossRefGoogle ScholarPubMed
Barnett, P, Matthews, H, Lloyd-Evans, B, et al. Compulsory community treatment to reduce readmission to hospital and increase engagement with community care in people with mental illness: a systematic review and meta-analysis. Lancet Psychiatr. 2018; 5(12): 1013–1022.CrossRefGoogle ScholarPubMed
Swartz, MS, Wilder, CM, Swanson, JW, et al. Assessing outcomes for consumers in New York’s assisted outpatient treatment program. Psychiatr Serv. 2010; 61(10): 976–81.10.1176/ps.2010.61.10.976CrossRefGoogle ScholarPubMed
Segal, SP, Rimes, L, Hayes, SL. The utility of outpatient commitment: reduced-risks of victimization and crime perpetration. Eur Psychiatry. 2019; 56: 97–104.CrossRefGoogle ScholarPubMed